Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU

Date: 26/03/2021
Location: Virtual meeting, 13:00 - 15:15 (CET)

Event summary

This third public meeting updated EU citizens about the continued assessment, approval and safety monitoring of COVID-19 vaccines, and their expected impact at community level.

It covered: 

  • COVID-19 vaccines approved in the EU and those currently under review;
  • post-authorisation activities, including emerging safety data since EU authorisation of the first COVID-19 vaccines;
  • ongoing work to address new variants;
  • the expected impact of COVID-19 vaccination on our society;
  • transparency and the publication of clinical data for COVID-19 vaccines.

The event also allowed the public and stakeholders to further inform EMA of their needs, expectations and any concerns.

Video recordings

Full video recording

 

Update on approved and candidate COVID-19 vaccines in the EU, Marco Cavaleri (EMA)

 

Vaccines safety monitoring – update on emerging data since EU authorisations, Peter Arlett (EMA)

 

Expected impact of COVID-19 vaccination in the European Union, Edoardo Colzani (ECDC)

 

Transparency and publication of clinical data for COVID-19 vaccines, Melanie Carr (EMA)

Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to the European Medicines Agency instead.

Order